PL3583943T3 - Kompozycja farmaceutyczna - Google Patents

Kompozycja farmaceutyczna

Info

Publication number: PL3583943T3
Authority: PL; Poland
Prior art keywords: pharmaceutical composition; pharmaceutical; composition
Prior art date: 2017-02-15

Application number

PL18755023.1T

Other languages

English (en)

Inventor

Shinji Okada

Original Assignee

Taiho Pharmaceutical Co., Ltd.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-02-15

Filing date

2018-02-14

Publication date

2024-11-25

2018-02-14 Application filed by Taiho Pharmaceutical Co., Ltd. filed Critical Taiho Pharmaceutical Co., Ltd.

2024-11-25 Publication of PL3583943T3 publication Critical patent/PL3583943T3/pl

Links

239000008194 pharmaceutical composition Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/04—Nitro compounds

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Inorganic Chemistry (AREA)
Physical Education & Sports Medicine (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

PL18755023.1T 2017-02-15 2018-02-14 Kompozycja farmaceutyczna PL3583943T3 (pl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2017026203		2017-02-15
PCT/JP2018/005140 WO2018151177A1 (ja)	2017-02-15	2018-02-14	医薬組成物

Publications (1)

Publication Number	Publication Date
PL3583943T3 true PL3583943T3 (pl)	2024-11-25

Family

ID=63169269

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL18755023.1T PL3583943T3 (pl)	2017-02-15	2018-02-14	Kompozycja farmaceutyczna

Country Status (20)

Country	Link
US (2)	US11110062B2 (pl)
EP (1)	EP3583943B1 (pl)
JP (1)	JP6771594B2 (pl)
KR (2)	KR20210135354A (pl)
CN (2)	CN117137915A (pl)
AU (1)	AU2018222163C1 (pl)
CA (1)	CA3053739C (pl)
DK (1)	DK3583943T3 (pl)
ES (1)	ES2991062T3 (pl)
FI (1)	FI3583943T3 (pl)
HU (1)	HUE068810T2 (pl)
MA (1)	MA47516A (pl)
MX (2)	MX2021007061A (pl)
MY (1)	MY194278A (pl)
PH (1)	PH12019501873A1 (pl)
PL (1)	PL3583943T3 (pl)
PT (1)	PT3583943T (pl)
SG (1)	SG11201907433TA (pl)
TW (1)	TWI702951B (pl)
WO (1)	WO2018151177A1 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK3583943T3 (da)	2017-02-15	2024-10-14	Taiho Pharmaceutical Co Ltd	Farmaceutisk sammensætning
EP3682882A4 (en)	2017-09-08	2021-06-02	Taiho Pharmaceutical Co., Ltd.	ANTI-TUMOR AGENT AND ANTI-TUMOR POTENTIALIZER
KR20210060465A (ko)	2018-09-18	2021-05-26	다이호야쿠힌고교 가부시키가이샤	아실티오우레아 화합물과 아비라테론의 병용 요법
TWI872203B (zh) *	2020-02-14	2025-02-11	日商大鵬藥品工業股份有限公司	醯基硫脲化合物的製造方法
KR20220128310A (ko)	2021-03-12	2022-09-20	주식회사 엘지에너지솔루션	버스바 어셈블리, 이러한 버스바 어셈블리를 포함하는 배터리 팩 및 이러한 배터리 팩을 포함하는 자동차
US20230114887A1 (en)	2021-10-12	2023-04-13	Lg Energy Solution, Ltd.	Battery pack and vehicle including the same

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5254541A (en)	1991-11-15	1993-10-19	Merck Frosst Canada, Inc.	(Quinolin-2-ylmethoxy)indole/cyclodextrin complex
CN1154070A (zh) *	1994-05-27	1997-07-09	荷兰发马克有限公司	药物组合物
EP1243582A4 (en)	1999-12-24	2003-06-04	Kirin Brewery	CHINOLINE AND CHINAZOLINE DERIVATIVES AND MEDICATIONS CONTAINING THEM
KR100600550B1 (ko)	2000-10-20	2006-07-13	에자이 가부시키가이샤	질소 함유 방향환 유도체
CA2454538A1 (en)	2001-06-22	2003-01-03	Kirin Beer Kabushiki Kaisha	Quinoline derivatives and quinazoline derivatives capable of inhibiting autophosphorylation of hepatocyte growth factor receptors, and pharmaceutical composition comprising the same
SE520606C2 (sv)	2001-06-26	2003-07-29	Flir Systems Ab	Förfarande för att åstadkomma en spegelyta, samt spegel med sådan spegelyta
JP2003238592A (ja)	2001-12-13	2003-08-27	Japan Tobacco Inc	組織及び血管の再生のための医薬及びその方法
CN1448053A (zh) *	2003-04-22	2003-10-15	西安敬业生物药物科技有限公司	甲基托布津包络物农药制剂
EP2210607B1 (en)	2003-09-26	2011-08-17	Exelixis Inc.	N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
KR100799534B1 (ko)	2004-02-27	2008-01-31	에자이 알앤드디 매니지먼트 가부시키가이샤	신규 피리딘 유도체 및 피리미딘 유도체(1)
WO2005105044A1 (en) *	2004-04-30	2005-11-10	Ranbaxy Laboratories Limited	Process for making inclusion complex of sulfonylureas having improved aqueous solubility
WO2005121125A1 (en)	2004-06-09	2005-12-22	Pfizer Inc.	Ether-linked heteroaryl compounds
US20050288290A1 (en)	2004-06-28	2005-12-29	Borzilleri Robert M	Fused heterocyclic kinase inhibitors
CN100448053C (zh) *	2004-08-31	2008-12-31	清华大学	含有屏蔽掩膜支撑体的有机电致发光器件及其制备方法
AU2006229343A1 (en)	2005-03-28	2006-10-05	Kirin Pharma Kabushiki Kaisha	Thienopyridine derivative, or quinoline derivative, or quinazoline derivative, having c-Met autophosphorylation inhibiting potency
WO2006108059A1 (en)	2005-04-06	2006-10-12	Exelixis, Inc.	C-met modulators and methods of use
US7728017B2 (en)	2005-11-30	2010-06-01	Vertex Pharmaceuticals Incorporated	Inhibitors of c-Met and uses thereof
EP2215085B1 (en)	2007-10-25	2011-09-07	AstraZeneca AB	Pyridine and pyrazine derivatives useful in the treatment of cell proliferative disorders
CN101491240A (zh) *	2008-01-25	2009-07-29	国家农产品保鲜工程技术研究中心（天津）	提高纳他霉素作用效率的方法
WO2009096377A1 (ja)	2008-01-29	2009-08-06	Eisai R & D Management Co., Ltd.	血管阻害物質とタキサンとの併用
SG188802A1 (en)	2008-03-06	2013-04-30	Genentech Inc	Combination therapy with c-met and egfr antagonists
JP4667537B2 (ja)	2008-04-10	2011-04-13	大鵬薬品工業株式会社	アシルチオウレア化合物又はその塩、及びその用途
UY31800A (es)	2008-05-05	2009-11-10	Smithkline Beckman Corp	Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
WO2009140549A1 (en)	2008-05-14	2009-11-19	Amgen Inc.	Combinations vegf(r) inhibitors and hepatocyte growth factor (c-met) inhibitors for the treatment of cancer
UY32049A (es)	2008-08-14	2010-03-26	Takeda Pharmaceutical	Inhibidores de cmet
BR122020021551B1 (pt) *	2008-11-15	2021-09-21	Melinta Subsidiary Corp	Composição farmacêutica antimicrobiana e seu uso
CA2752232C (en)	2009-02-12	2016-11-22	Arqule, Inc.	A composition comprising (-)-trans-3-(5,6-dihydro-4h-pyrrolo [3,2,1-ij] quinolin-1-yl)-4-(1h-indol-3-yl) pyrrolidine-2, 5-dione in combination with a second anti-proliferative agent
CN101926808A (zh) *	2009-06-25	2010-12-29	积华药业有限公司	氨基葡萄糖制剂
MX2012008898A (es)	2010-02-03	2012-11-06	Incyte Corp	Imidazo - [1, 2 - b] [1, 2, 4] triazinas como inhibidores de c - met.
JP5960688B2 (ja)	2010-05-17	2016-08-02	インコゼンセラピューティクスプライベートリミテッド	プロテインキナーゼ調節物質としての新規３，５−二置換−３ｈ−［１，２，３］トリアゾロ［４，５−ｂ］ピリジン化合物
CN102274189A (zh) *	2011-07-21	2011-12-14	瑞普（天津）生物药业有限公司	一种含有癸氧喹酯的干混悬剂组方及其制备方法
CN110292575B (zh) *	2011-10-18	2022-05-13	株式会社AskAt	药物组合物
TWI594986B (zh)	2011-12-28	2017-08-11	Taiho Pharmaceutical Co Ltd	Antineoplastic agent effect enhancer
RU2494470C1 (ru)	2012-04-04	2013-09-27	Общество с ограниченной ответственностью "Саентифик Фьючер Менеджмент" (ООО "Саентифик Фьючер Менеджмент")	Способ лечения фиброза легких
AU2014292086B2 (en) *	2013-07-19	2019-08-08	Boehringer Ingelheim Vetmedica Gmbh	Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition
US9149471B2 (en)	2013-09-30	2015-10-06	National University Corporation Tokyo University Of Agriculture And Technology	Therapeutic agent for osteoporosis
EP3114144A1 (en)	2014-03-05	2017-01-11	Bristol-Myers Squibb Company	Treatment of renal cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
CN107427515B (zh)	2014-12-03	2021-11-16	奥克兰联合服务有限公司	用于治疗癌症的激酶抑制剂前药
KR20240064733A (ko)	2015-03-04	2024-05-13	머크 샤프 앤드 돔 코포레이션	암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
JP2016196411A (ja)	2015-03-04	2016-11-24	エーザイ・アール・アンド・ディー・マネジメント株式会社	腫瘍治療剤
WO2016175305A1 (ja) *	2015-04-30	2016-11-03	大鵬薬品工業株式会社	アシルチオウレア化合物のメシル酸塩及びその結晶並びにそれらの製造方法
BR112017028137B1 (pt)	2015-06-25	2023-04-04	Taiho Pharmaceutical Co., Ltd	Uso de 4-[2-fluoro-4-[[[(2-fenilacetil)amino]tioxometil]amino]- fenóxi]-7-metóxi-n-metil-6-quinolinacarboxamida ou um sal deste
JP6804832B2 (ja)	2015-07-21	2020-12-23	東芝ライフスタイル株式会社	冷蔵庫
CN106551911A (zh) *	2015-09-21	2017-04-05	天津市汉康医药生物技术有限公司	一种稳定的乐伐替尼药物组合物及其制备方法
DK3583943T3 (da)	2017-02-15	2024-10-14	Taiho Pharmaceutical Co Ltd	Farmaceutisk sammensætning

2018
- 2018-02-14 DK DK18755023.1T patent/DK3583943T3/da active
- 2018-02-14 CA CA3053739A patent/CA3053739C/en active Active
- 2018-02-14 TW TW107105612A patent/TWI702951B/zh active
- 2018-02-14 AU AU2018222163A patent/AU2018222163C1/en active Active
- 2018-02-14 MY MYPI2019004652A patent/MY194278A/en unknown
- 2018-02-14 CN CN202311298292.7A patent/CN117137915A/zh active Pending
- 2018-02-14 US US16/485,971 patent/US11110062B2/en active Active
- 2018-02-14 MA MA047516A patent/MA47516A/fr unknown
- 2018-02-14 WO PCT/JP2018/005140 patent/WO2018151177A1/ja not_active Ceased
- 2018-02-14 HU HUE18755023A patent/HUE068810T2/hu unknown
- 2018-02-14 ES ES18755023T patent/ES2991062T3/es active Active
- 2018-02-14 JP JP2018568583A patent/JP6771594B2/ja active Active
- 2018-02-14 MX MX2021007061A patent/MX2021007061A/es unknown
- 2018-02-14 PT PT187550231T patent/PT3583943T/pt unknown
- 2018-02-14 EP EP18755023.1A patent/EP3583943B1/en active Active
- 2018-02-14 FI FIEP18755023.1T patent/FI3583943T3/fi active
- 2018-02-14 SG SG11201907433TA patent/SG11201907433TA/en unknown
- 2018-02-14 MX MX2019009717A patent/MX383728B/es unknown
- 2018-02-14 KR KR1020217035697A patent/KR20210135354A/ko not_active Ceased
- 2018-02-14 CN CN201880012000.XA patent/CN110312511B/zh active Active
- 2018-02-14 KR KR1020197023592A patent/KR102323255B1/ko active Active
- 2018-02-14 PL PL18755023.1T patent/PL3583943T3/pl unknown
2019
- 2019-08-13 PH PH12019501873A patent/PH12019501873A1/en unknown
2021
- 2021-06-15 US US17/347,989 patent/US12144892B2/en active Active

Also Published As

Publication number	Publication date
KR20210135354A (ko)	2021-11-12
KR102323255B1 (ko)	2021-11-08
SG11201907433TA (en)	2019-09-27
MA47516A (fr)	2021-03-31
KR20190113831A (ko)	2019-10-08
US12144892B2 (en)	2024-11-19
CA3053739C (en)	2023-02-14
JP6771594B2 (ja)	2020-10-21
EP3583943B1 (en)	2024-09-18
FI3583943T3 (fi)	2024-10-29
MX2021007061A (es)	2022-10-07
PT3583943T (pt)	2024-10-15
RU2019125612A (ru)	2021-03-16
DK3583943T3 (da)	2024-10-14
TWI702951B (zh)	2020-09-01
EP3583943A1 (en)	2019-12-25
HUE068810T2 (hu)	2025-01-28
CN110312511A (zh)	2019-10-08
AU2018222163B2 (en)	2021-01-28
BR112019016764A2 (pt)	2020-03-31
US11110062B2 (en)	2021-09-07
WO2018151177A1 (ja)	2018-08-23
EP3583943A4 (en)	2020-12-30
MX2019009717A (es)	2019-10-02
MX383728B (es)	2025-03-14
MY194278A (en)	2022-11-25
ES2991062T3 (es)	2024-12-02
US20200060973A1 (en)	2020-02-27
PH12019501873A1 (en)	2020-06-15
US20210308056A1 (en)	2021-10-07
AU2018222163C1 (en)	2021-08-12
CA3053739A1 (en)	2018-08-23
JPWO2018151177A1 (ja)	2019-11-07
CN110312511B (zh)	2023-10-27
CN117137915A (zh)	2023-12-01
AU2018222163A1 (en)	2019-09-05
RU2019125612A3 (pl)	2021-03-16
TW201836608A (zh)	2018-10-16

Publication	Publication Date	Title
IL265260B (en)	2022-05-01	pharmaceutical preparations
IL265360B (en)	2022-10-01	Pharmaceutical composition
IL269061A (en)	2019-11-28	A pharmaceutical preparation containing Selexifag
IL271986B1 (en)	2023-04-01	pharmaceutical preparation
IL262654A (en)	2018-12-31	Pharmacy preparation
IL265349A (en)	2019-05-30	Pharmaceutical composition
HUE055884T2 (hu)	2021-12-28	Gyógyszerkészítmény
GB201712159D0 (en)	2017-09-13	Pharmaceutical composition
GB201705303D0 (en)	2017-05-17	Pharmaceutical compositions
HUE068810T2 (hu)	2025-01-28	Gyógyászati készítmény
GB201705304D0 (en)	2017-05-17	Pharmaceutical compositions
IL272419A (en)	2020-03-31	Pharmaceutical composition
GB201719447D0 (en)	2018-01-10	Pharmaceutical composition
GB201705305D0 (en)	2017-05-17	Pharmaceutical compositions
GB201705306D0 (en)	2017-05-17	Pharmaceutical compositions
PL3646867T3 (pl)	2025-02-17	Kompozycja farmaceutyczna
PL3454838T3 (pl)	2020-09-21	Kompozycja farmaceutyczna
GB201615917D0 (en)	2016-11-02	Pharmaceutical composition
GB201615914D0 (en)	2016-11-02	Pharmaceutical composition
IL271513A (en)	2020-02-27	Innovative pharmaceutical composition
IL265436B (en)	2022-06-01	Pharmacy preparation
GB201615910D0 (en)	2016-11-02	Pharmaceutical composition
GB201620519D0 (en)	2017-01-18	Pharmaceutical composition
IL265428A (en)	2019-05-30	Pharmaceutical composition
GB201708328D0 (en)	2017-07-05	Pharmaceutical composition